Basic 115.0 % 16.0 %
Diluted 115.0 % 16.3 %
Weighted Average Common Shares Outstanding:
Basic 1.5 % 1.5 %
Diluted 1.3 % 1.3 %
A -- Includes intangible assets amortization of $15.9 related to the Mayne
Pharma acquisition; charges of $9.2 related to the planned closures
of the Ashland, OH; Montreal, Canada; North Chicago, IL; and Morgan
Hill, CA facilities as well as charges to limit, and transfer, R&D
facility operations related to brain-function monitoring devices as
part of Hospira's facilities optimization initiatives; and Mayne
Pharma and other acquisition integration charges of $2.6.
B -- Includes acquisition integration charges of $0.4 and facilities
optimization initiatives of $0.7.
C -- Acquired in-process research and development.
D -- Acquisition integration charges.
E -- Reflects the tax effect of the above adjustments.
F -- Includes inventory step-up charge of $31.7 and intangible assets
amortization of $13.2 related to the Mayne Pharma acquisition;
charges of $14.6 related to the planned closures of the Donegal,
Ireland; Ashland, OH; Montreal, Canada; and North Chicago, IL
facilities as part of Hospira's facilities optimization initiatives;
a reduction of the obligation associated with the sale of the Salt
Lake City, UT manufacturing plant to ICU Medical ($1.6); and Mayne
Pharma integration charges of $4.1.
nm = Percent change is not meaningful.
Reconciliation of Condensed Consolidated Statements of Income
|SOURCE Hospira, Inc.|
Copyright©2008 PR Newswire.
All rights reserved